PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):e137-40. doi: 10.1016/j.clml.2015.06.007. Epub 2015 Jun 19.

¹ Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
² Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
³ Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX; Simmons Cancer Center, Division of Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
⁴ Simmons Cancer Center, Division of Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
⁵ Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX; Simmons Cancer Center, Division of Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: harris.naina@utsouthwestern.edu.

No abstract available

Keywords: CLL; Denosumab; Humoral hypercalcemia; Hypercalcemia of malignancy; PTHrP; Parathyroid hormone–related protein.

Publication types